Sphingosine-1-phosphate signaling in endothelial disorders

Current Atherosclerosis Reports

Volumn 18, Issue 6, 2016, Pages

  Sanchez, Teresa ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Blood brain barrier; Brain edema; Coronary artery disease; Hemorrhagic transformation; Malignant middle cerebral artery syndrome; Microvascular dysfunction; Neurovascular injury; Non reflow; Stroke reperfusion therapies; Vasogenic edema

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPASE C; PROTEIN KINASE B; RAC PROTEIN; RHO FACTOR; RHO KINASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CELL ACTIVATION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL SURVIVAL; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; MICROVASCULATURE; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR DISEASES; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HUMANS; LYSOPHOSPHOLIPIDS; MICROVESSELS; SIGNAL TRANSDUCTION; SPHINGOSINE; VASCULAR DISEASES;

EID: 85008440626     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-016-0586-1     Document Type: Article

References (99)

1. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527-61.
2. Ye X, Ding J, Zhou X, Chen G, Liu SF. Divergent roles of endothelial nf-kappab in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med. 2008;205:1303-15.
3. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101:3765-77.
4. Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost. 2005;3:1392-406.
5. Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke. Stroke. 2007;38:3084-94.
6. Schwab S, Spranger M, Schwarz S, Hacke W. Barbiturate coma in severe hemispheric stroke: useful or obsolete? Neurology. 1997;48: 1608-13.
7. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem (Tokyo). 1997;121:969-73.
8. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316: 295-8.
9. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;352(Pt 3):809-15.
10. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by hdl-associated apolipoprotein m. Proc Natl Acad Sci U S A. 2011;108:9613-8. This study shows that Apo M is the carrier of S1P in HDL and contributes to their vasoprotective effects.
11. Yatomi Y, Ruan F, Hakomori S, Igarashi Y. Sphingosine-1-phos-phate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood. 1995;86:193-202.
12. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102:669-76.
13. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, et al. Sphingosine-1-phosphate as a ligand for the g protein-coupled receptor edg-1. Science. 1998;279:1552-5.
14. Sato K, Ui M, Okajima F. Differential roles of edg-1 and edg-5, sphingosine 1-phosphate receptors, in the signaling pathways in c6 glioma cells. Brain Res Mol Brain Res. 2000;85:151-60.
15. Kon J, Sato K, Watanabe T, Tomura H, Kuwabara A, Kimura T, et al. Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cdna-transfected Chinese hamster ovary cells. J Biol Chem. 1999;274:23940-7.
16. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25:11113-21.
17. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the g protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000;106:951-61.
18. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, et al. The sphingosine-1-phosphate receptors s1p1, s1p2, and s1p3 function coordinately during embryonic angiogenesis. J Biol Chem. 2004;279:29367-73.
19. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator fty720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-7.
20. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346-9.
21. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on s1p receptor 1. Nature. 2004;427:355-60.
22. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through s1p lyase inhibition and disruption of s1p gradients. Science. 2005;309:1735-9.
23. LaMontagne K, Littlewood-Evans A, Schnell C, O’Reilly T, Wyder L, Sanchez T, et al. Antagonism of sphingosine-1-phosphate receptors by fty720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006;66:221-31.
24. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282: 9082-9.
25. Windh RT, Lee MJ, Hla T, An S, Barr AJ, Manning DR. Differential coupling of the sphingosine 1-phosphate receptors edg-1, edg-3, and h218/edg-5 to the g(i), g(q), and g(12) families of heterotrimeric g proteins. J Biol Chem. 1999;274:27351-8.
26. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99: 301-12.
27. Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest. 2007;117:2506-16.
28. Kim GS, Yang L, Zhang G, Zhao H, Selim M, McCullough LD, et al. Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. Nat Commun. 2015;6:7893. This study showed the critical role of S1PR2 in the disruption of cerebrovascular integrity, the development of hemorrhagic transformation and the activation of matrix metalloproteinase-9 in the brain endothelium upon ischemia-reperfusion injury.
29. Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, et al. Sphingosine 1-phosphate activates akt, nitric oxide production, and chemotaxis through a gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276: 19672-7.
30. Paik JH, Chae S, Lee MJ, Thangada S, Hla T. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of edg-1 and edg-3 receptors and rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem. 2001;276:11830-7.
31. Shikata Y, Birukov KG, Birukova AA, Verin A, Garcia JG. Involvement of site-specific fak phosphorylation in sphingosine-1 phosphate- and thrombin-induced focal adhesion remodeling: role of src and git. FASEB J. 2003;17:2240-9.
32. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108:689-701.
33. Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, Zhan X, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem. 2004;279:24692-700.
34. Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of rac and cell motility by the g12/13-rho and gi pathways integrated downstream of a single g protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003;23:1534-45.
35. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (s1p) receptors, s1p(2)/lp(b2)/edg-5 and s1p(3)/lp(b3)/edg-3. J Biol Chem. 2002;277:25152-9.
36. Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, Wu H, et al. Pten as an effector in the signaling of antimigratory g proteincoupled receptor. Proc Natl Acad Sci U S A. 2005;102:4312-7.
37. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (s1p2r) and its downstream effectors rock and pten. Arterioscler Thromb Vasc Biol. 2007;27:1312-8.
38. Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, IshizukaT, et al. Role of scavenger receptor class b type i and sphingosine 1- phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem. 2006;281:37457-67.
39. Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, Whetzel A, et al. Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol. 2005;25:976-81.
40. Matsushita K, Morrell CN, Lowenstein CJ. Sphingosine 1-phosphate activates weibel-palade body exocytosis. Proc Natl Acad Sci U S A. 2004;101:11483-7.
41. Nussbaum C, Bannenberg S, Keul P, Graler MH, Goncalves-de- Albuquerque CF, Korhonen H, et al. Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial p-selectin. Nat Commun. 2015;6:6416.
42. Zhang G, Yang L, Kim GS, Ryan K, Lu S, O’Donnell RK, et al. Critical role of sphingosine-1-phosphate receptor 2 (s1pr2) in acute vascular inflammation. Blood. 2013;122:443-55. This study demonstrated the role of S1PR2 in the induction of endothelial permeability and inflammation via activation of the NF-κB and the stress activated protein kinase p38 pathways.
43. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001;276: 31780-5.
44. Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol. 2003;23:1283-8.
45. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, et al. High-density lipoprotein binding to scavenger receptor-bi activates endothelial nitric oxide synthase. Nat Med. 2001;7:853-7.
46. Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, et al. High density lipoprotein-associated sphingosine 1- phosphate promotes endothelial barrier function. J Biol Chem. 2008;283:25074-81.
47. Wilkerson BA, Grass GD, Wing SB, Argraves WS, Argraves KM. Sphingosine 1-phosphate (s1p) carrier-dependent regulation of endothelial barrier: High density lipoprotein (hdl)-s1p prolongs endothelial barrier enhancement as compared with albumin-s1p via effects on levels, trafficking, and signaling of s1p1. J Biol Chem. 2012;287:44645-53.
48. Galvani S, Sanson M, Blaho VA, Swendeman SL, Conger H, Dahlback B, et al. Hdl-bound sphingosine 1-phosphate acts as a biased agonistfor the endothelial cell receptor s1p1 to limit vascular inflammation. Sci Signal. 2015;8:ra79. This paper showed that HDL-bound S1P acts as a β-arrestin biased ligand leading to inhibition of endothelial inflammation. It was also shown that endothelial S1PR1 is anti-inflammatory in vivo and prevents the development of atherosclerosis in areas of laminar flow.
49. Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, Morris MA, Ley K, et al. Sphingosine-1 phosphate prevents monocyte/ endothelial interactions in type 1 diabetic nod mice through activation of the s1p1 receptor. Circ Res. 2006;99:731-9.
50. Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res. 2008.
51. Zhao Y, Gorshkova IA, Berdyshev E, He D, Fu P, Ma W, et al. Protection of lps-induced murine acute lung injury by sphingosine1-phosphate lyase suppression. Am J Respir Cell Mol Biol. 2011.
52. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein c through par1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105:3178-84.
53. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. Activated protein c mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005;280:17286-93.
54. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: role of mop-r and s1p3 transactivation. Am J Respir Cell Mol Biol. 2007;37:222-31.
55. Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE, et al. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female cns autoimmunity susceptibility. J Clin Invest. 2014;124:2571-84.
56. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A. 1998;95:14196-201.
57. Takeya H, Gabazza EC, Aoki S, Ueno H, Suzuki K. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood. 2003;102:1693-700.
58. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of hdl. Circ Res. 2004;95:764-72.
59. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201-11.
60. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, et al. Fty720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007;115:501-8.
61. Keul P, Tolle M, Lucke S, von Wnuck LK, Heusch G, Schuchardt M, et al. The sphingosine-1-phosphate analogue fty720 reduces atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607-13.
62. Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, Preusch M, et al. Sphingosine-1-phosphate analogue fty720 causes lymphocyte redistribution and hypercholesterolemia in apoe-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:2392-9.
63. Poti F, Gualtieri F, Sacchi S, Weissen-Plenz G, Varga G, Brodde M, et al. Krp-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in ldl-r−/− mice. Arterioscler Thromb Vasc Biol. 2013;33:1505-12.
64. Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:81-5.
65. Keul P, Lucke S, von Wnuck LK, Bode C, Graler M, Heusch G, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res. 2011;108:314-23.
66. Poti F, Ceglarek U, Burkhardt R, Simoni M, Nofer JR. Ski-ii - a sphingosine kinase 1 inhibitor—exacerbates atherosclerosis in low- density lipoprotein receptor-deficient (ldl-r) mice on high cholesterol diet. Atherosclerosis. 2015;240:212-5.
67. Poti F, Bot M, Costa S, Bergonzini V, Maines L, Varga G, et al. Sphingosine kinase inhibition exerts both pro-and anti-atherogenic effects in low-density lipoprotein receptor-deficient mice. Thromb Haemost. 2012;107:552-61.
68. Bot M, Van Veldhoven PP, de Jager SC, Johnson J, Nijstad N, Van Santbrink PJ, et al. Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in ldlreceptor deficient mice. PLoS One. 2013;8, e63360.
69. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, et al. Phosphorylation and action of the immune-modulator fty720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem. 2003;278:47281-90.
70. Jung B, Obinata H, Galvani S, Mendelson K, Ding BS, Skoura A, et al. Flow-regulated endothelial s1p receptor-1 signaling sustains vascular development. Dev Cell. 2012;23:600-10.
71. Michaud J, Im DS, Hla T. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol. 2010;184:1475-83.
72. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral s1p1 antagonist in vivo. Nat Chem Biol. 2006;2:434-41.
73. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the s1p3 lysophospholipid receptor. Circulation. 2006;114:1403-9.
74. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck LK, Baba HA, et al. Hdl induces no-dependent vasorelaxation via the lysophospholipid receptor s1p3. J Clin Invest. 2004;113:569-81.
75. Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J. 2003;146:62-8.
76. Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, et al. Sphingosine 1-phosphate levels in plasma and hdl are altered in coronary artery disease. Basic Res Cardiol. 2010;105:821-32.
77. Argraves KM, Sethi AA, Gazzolo PJ, Wilkerson BA, Remaley AT, Tybjaerg-Hansen A, et al. S1p, dihydro-s1p and c24:1-ceramide levels in the hdl-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011;10:70.
78. Knapp M, Baranowski M, Czarnowski D, Lisowska A, Zabielski P, Gorski J, et al. Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit. 2009;15:CR490-3.
79. Sugiura T, Dohi Y, Yamashita S, Ohte N, Ito S, Iwaki S, et al. Analytical evaluation of plasma serotonin and sphingosine 1-phosphate and their clinical assessment in early atherosclerosis. Coron Artery Dis. 2012;23:234-8.
80. Sattler K, Lehmann I, Graler M, Brocker-Preuss M, Erbel R, Heusch G, et al. Hdl-bound sphingosine 1-phosphate (s1p) predicts the severity of coronary artery atherosclerosis. Cell Physiol Biochem. 2014;34:172-84. This paper showed that the content of S1P in HDL from CAD patients negatively correlated with the severity of the disease and low HDL-bound S1P predicted the severity of CAD.
81. Sattler K, Graler M, Keul P, Weske S, Reimann CM, Jindrova H, et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015;66: 1470-85. This study showed that, in patients with CAD, the reduced S1P content in HDL contributes to HDL dysfunction which could be corrected by S1P loading.
82. Saver JL. Improving reperfusion therapy for acute ischaemic stroke. J Thromb Haemost. 2011;9 Suppl 1:333-43.
83. Molina CA, Alvarez-Sabin J. Recanalization and reperfusion therapies for acute ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 1: 162-7.
84. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab. 1996;16:1373-8.
85. Ames 3rd A, Wright RL, Kowada M, Thurston JM, Majno G. Cerebral ischemia. Ii. The no-reflow phenomenon. Am J Pathol. 1968;52:437-53.
86. del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23:879-94.
87. Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel MA, Kahles T, Neumann-Haefelin T, et al. The immunomodulatory sphingosine 1-phosphate analog fty720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009;389:251-6.
88. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Activation of sphingosine 1-phosphate receptor-1 by fty720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41:368-74.
89. Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011.
90. Liesz A, Sun L, Zhou W, Schwarting S, Mracsko E, Zorn M, et al. Fty720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS One. 2011;6, e21312.
91. Campos F, Qin T, Castillo J, Seo JH, Arai K, Lo EH, et al. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke. 2013;44:505-11.
92. Kraft P, Gob E, Schuhmann MK, Gobel K, Deppermann C, Thielmann I, et al. Fty720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuro-protection. Stroke. 2013;44:3202-10.
93. Cai A, Schlunk F, Bohmann F, Kashefiolasl S, Brunkhorst R, Foerch C, et al. Coadministration of fty720 and rt-pa in an experimental model of large hemispheric stroke-no influence on functional outcome and blood-brain barrier disruption. Exp Transl Stroke Med. 2013;5:11.
94. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 2014;111:18315-20.
95. Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, et al. Combination of an immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015.
96. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. Fty720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (s1p1) modulation. Proc Natl Acad Sci U S A. 2011;108:751-6.
97. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al. Oral fingolimod (fty720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-40.
98. Vogelgesang A, Grunwald U, Langner S, Jack R, Broker BM, Kessler C, et al. Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke. 2008;39: 237-41.
99. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke. 2007;38:770-3.